Targeted gene panel and genotype-phenotype correlation in … · 2020. 7. 3. · of epilepsy...
Transcript of Targeted gene panel and genotype-phenotype correlation in … · 2020. 7. 3. · of epilepsy...
저 시-비 리- 경 지 2.0 한민
는 아래 조건 르는 경 에 한하여 게
l 저 물 복제, 포, 전송, 전시, 공연 송할 수 습니다.
다 과 같 조건 라야 합니다:
l 하는, 저 물 나 포 경 , 저 물에 적 된 허락조건 명확하게 나타내어야 합니다.
l 저 터 허가를 면 러한 조건들 적 되지 않습니다.
저 에 른 리는 내 에 하여 향 지 않습니다.
것 허락규약(Legal Code) 해하 쉽게 약한 것 니다.
Disclaimer
저 시. 하는 원저 를 시하여야 합니다.
비 리. 하는 저 물 리 목적 할 수 없습니다.
경 지. 하는 저 물 개 , 형 또는 가공할 수 없습니다.
Targeted gene panel and genotype-phenotype
correlation in children with developmental and
epileptic encephalopathy
Ara Ko
Department of Medicine
The Graduate School, Yonsei University
[UCI]I804:11046-000000516567[UCI]I804:11046-000000516567
Targeted gene panel and genotype-phenotype
correlation in children with developmental and
epileptic encephalopathy
Ara Ko
Department of Medicine
The Graduate School, Yonsei University
Targeted gene panel and genotype-phenotype
correlation in children with developmental and
epileptic encephalopathy
Directed by Professor Hoon-Chul Kang
The Master's Thesis
submitted to the Department of Medicine,
the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree of Master of
Medical Science
Ara Ko
June 2018
ACKNOWLEDGEMENTS
I’d like to show my appreciation to my thesis advisor, Dr. Hoon-Chul
Kang for directing me through this work and being my role model as a
doctor, researcher, and educator.
For everything else, I thank my parents for literally everything.
<TABLE OF CONTENTS>
ABSTRACT ····································································· 1
I. INTRODUCTION ···························································· 2
II. PATIENTS AND METHODS ·············································· 2
1. Patients ···································································· 2
2. Targeted NGS gene panel ·············································· 3
3. Clnical characteristics ··················································· 3
4. Statistical analysis ······················································· 4
III. RESULTS ·································································· 4
1. Demographics and general characteristics ························· 4
2. Genotype-phenotype correlations ···································· 7
3. SCN1A ··································································· 8
4. CDKL5 ··································································· 8
5. CHD2 ···································································· 9
6. KCNQ2 ··································································· 9
7. STXBP1 ·································································· 10
8. SCN2A ··································································· 10
9. SCN8A ··································································· 10
10. SYNGAP1 ······························································ 11
IV. DISCUSSION ······························································ 13
V. CONCLUSION ····························································· 15
REFERENCES ································································· 16
APPENDICES ·································································· 19
ABSTRACT (IN KOREAN) ················································ 28
PUBLICATION LIST ························································ 29
LIST OF FIGURES
Figure 1. Age distribution of seizure onset in 103 patients with
identified pathogenic mutations ··································· 6
Figure 2. Positivity rate of targeted gene-panel sequencing for
developmental and epileptic encephalopathy according to
epilepsy syndromes ·················································· 6
Figure 3. Genotype-phenotype correlations ····················· 7
Figure 4. Age of seizure onset according to genes identified with
pathogenic mutations ················································ 9
LIST OF TABLES
Table 1. Identified pathogenic mutations ························ 5
Table 2. Demographic characteristics of patients with develop-
mental and epileptic encephalopathy and comparison between
patients with positive and negative results from targeted gene-
panel sequencing ······················································ 5
Table 3. Clinical characteristic of the eight most frequently iden-
tified genotypes ························································ 12
1
ABSTRACT
Targeted gene panel and genotype-phenotype correlation in children with
developmental and epileptic encephalopathy
Ara Ko
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Hoon-Chul Kang)
We performed targeted gene-panel sequencing for children with developmental and
epileptic encephalopathy (DEE) and evaluated the clinical implications of
genotype–phenotype correlations.
We assessed 278 children with DEE using a customized gene panel that included 172
genes, and extensively reviewed their clinical characteristics, including therapeutic
efficacy, according to genotype.
In 103 (37.1%) of the 278 patients with DEE, 35 different disease-causing monogenic
mutations were identified. The diagnostic yield was higher among patients who were
younger at seizure onset, especially those whose seizures started during the neonatal
period, and in patients with drug-resistant epilepsy. According to epilepsy syndromes,
the diagnostic yield was the highest among patients with West syndrome (WS) with a
history of neonatal seizures and mutations in KCNQ2 and STXBP1 were most frequently
identified. On the basis of genotypes, we evaluated the clinical progression and seizure
outcomes with specific therapeutic regimens; these were similar to those reported
previously. In particular, sodium channel blockers were effective in patients with
mutations in KCNQ2 and SCN2A in infancy, as well as SCN8A, and interestingly, the
ketogenic diet also showed diverse efficacy for patients with SCN1A, CDKL5, KCNQ2,
STXBP1, and SCN2A mutations. Unfortunately, quinidine was not effective in 2 patients
with migrating focal epilepsy in infancy related to KCNT1 mutations.
Targeted gene-panel sequencing is a useful diagnostic tool for DEE in children, and
genotype–phenotype correlations are helpful in anticipating the clinical progression and
treatment efficacy among these patients.
----------------------------------------------------------------------------------------
Key words: epileptic encephalopathy, NGS, genotype-phenotype
2
Targeted gene panel and genotype-phenotype correlation in children with
developmental and epileptic encephalopathy
Ara Ko
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Hoon-Chul Kang)
I. INTRODUCTION
Epileptic encephalopathy refers to a group of severe pediatric epilepsies in which
epileptic activities contribute to cognitive delay or regression.1 Recently, developmental and
epileptic encephalopathy (DEE) was introduced as a new concept, because cognitive
deterioration can also derive from genetic etiologies, irrespective of epileptic activity.1 With
advances in sequencing methods, monogenic mutations responsible for DEE have been
identified, suggesting underlying genetic etiologies in DEE patients who were previously
included in the unknown etiology group.2 Advanced sequencing methods have shortened the
diagnostic process, and potential benefits from gene-based determination of clinical progression
and therapeutic regimens might be expected in this era of emerging precision medicine.
Therefore, here, we sought to elaborate our single-center experience of using targeted
gene-panel sequencing to diagnose the genetic etiology of DEE and to reveal the clinical
implications of gene-panel studies by extensively reviewing genotypephenotype correlations in
such patients.
II. PATIENTS AND METHODS
II-1. Patients
A total of 280 unrelated pediatric patients with early-onset DEE of unknown etiology
were recruited from the epilepsy clinic of Severance Children’s Hospital between March 2015
and June 2017. All patients met the following criteria: (1) seizure onset before the age of 3
years; (2) multiple epileptiform discharges with severely disorganized background activity on
electroencephalography (EEG); (3) progressive developmental deterioration or a known
developmental and epileptic encephalopathy syndrome; (4) no significant structural lesion
detected on brain magnetic resonance imaging; (5) no metabolic abnormalities; and (6) no
abnormalities detected on previous genetic tests. This study was approved by the Institutional
3
Review Board of Severance Hospital.
II-2. Targeted NGS gene panel
A total of 172 genes known to be related to DEE were included in our gene panel; the
genes are listed in Appendix 1. Briefly, the processes for analyzing the sequencing data were as
follows. Genomic DNA was extracted from the leukocytes of whole-blood samples using the
QIAamp Blood DNA mini kit (Qiagen, Hilden, Germany). The pooled libraries were sequenced
using a MiSeq sequencer (Illumina, San Diego, CA, USA) and the MiSeq Reagent Kit v2 (300
cycles). Sequencing data were aligned against appropriate reference sequences and analyzed
using Sequencher 5.3 software (Gene Codes Corp., Ann Arbor, MI, USA).
Parental studies were performed by Sanger sequencing on a 3730 DNA Analyzer with
the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA)
if needed. Large exonic deletions and duplications were confirmed using the MLPA kit (MRC
Holland). Classification of the variants followed a three-step approach: (1) conventional
bioinformatics analysis, based on the nature of the mutation and frequencies in the normal
population; (2) in silico analysis, with a literature review of the same variant and other variants
in the same amino acid position; (3) a consensus discussion of genotypephenotype correlations
between geneticists and epileptologists, along with family studies and other confirmatory assays.
Subsequently, the variants determined to be pathogenic or to be likely pathogenic on the basis of
the American College of Medical Genetics and Genomics and the Association for Molecular
Pathology classification were considered as causative mutations for DEE.3
II-3. Clinical characteristics
We reviewed the clinical features of DEE patients investigated using targeted
gene-panel sequencing. The clinical characteristics included demographic profiles, classification
of epilepsy syndromes, and seizure outcomes after therapeutic regimens and diet therapy. For
epilepsy syndromes, the patients were classified according to the 2010 International League
Against Epilepsy classification.4 If the patient’s syndromic diagnoses changed over time, the
first syndromic diagnosis was selected. Patients who developed seizures during the neonatal
period and could not readily be categorized according to a syndrome but later developed West
syndrome (WS) were grouped separately as “WS with neonatal seizures.” Drug-resistant
epilepsy was defined as failure to achieve seizure freedom after adequate trials with 2
antiepileptic drugs. With regard to the efficacy of the therapeutic regimens, including diet
therapy, we considered the regimens as effective if they contributed to more than 50% decrease
in the seizure frequency from the baseline.
4
II-4. Statistical analysis
Data from statistical analyses are expressed as medians and interquartile ranges (IQRs)
for continuous and ordinal variables, and as counts and percentages for categorical variables.
The 2 groups were compared using the Chi-square test or Fisher’s exact tests for categorical and
ordinal data, or the Mann–Whitney U-test for non-parametric continuous data. A p value of <
0.05 was considered significant. The Statistical Package for the Social Sciences (version 23.0;
SPSS Inc., Chicago, IL, USA) was used for all analysis.
III. RESULTS
III-1. Demographics and general characteristics
Among the 278 patients (268 Koreans, 1 Mongolian, and 9 Caucasians),
pathogenic monogenic mutations were identified in 103 (37.1%). Thirty-five different causative
genes were found, with SCN1A being the most frequent (n = 11, 10.7%), followed by CDKL5 (n
= 9, 8.7%), CHD2 (n = 8, 7.8%), KCNQ2 (n = 7, 6.8%), STXBP1 (n = 7, 6.8%), SCN2A (n = 5,
4.9%), SCN8A (n = 5, 4.9%), SYNGAP1 (n = 5, 4.9%), and others (Table 1). Thirty-four (33.0%)
of 103 patients with identified mutations carried variants that had not been previously reported,
which were therefore confirmed to be de novo mutations by trio sequencing. All pathogenic
variants detected in this study are listed in the Appendix 2.
When the 103 patients with identified mutations were compared with the 175 patients
who showed negative findings in the gene panel screen, the age of seizure onset was
significantly earlier (p = 0.039) and the proportion of patients showing drug-resistant epilepsy
was significantly larger (p < 0.001) among patients with identified mutations (Table 2). After
controlling with age at seizure onset, presence of drug-resistant epilepsy, sex, and epilepsy
syndrome, age of seizure onset (OR 0.977, 95% CI 0.957-0.996, p = 0.019) and presence of
drug-resistant epilepsy (OR 3.036, 95% CI 1.544-5.970, p = 0.001) were still significant
predictors of achieving genetic diagnosis with gene panel study. The diagnostic yield was
highest in patients with seizure onset during the neonatal period, with 80.0% (20 of 25) of
patients proven to have causative mutations. This was significantly higher when compared to
the patients whose seizures began after 30 days of age who shows a diagnostic yield of 32.8% (p
< 0.001). The proportions of identified gene mutations decreased as the age at seizure onset
increased (Figure 1).
5
Table 1. Identified pathogenic mutations (n = 103, 35 genes)
Pathogenic gene n (%) Pathogenic gene n (%)
ALDH7A1 2 (1.9) KCNT1 3 (2.9)
ARX 1 (1.0) MECP2 5 (4.9)
BRAT1 3 (2.9) PCDH19 3 (2.9)
CACNA1A 1 (1.0) PRODH 1 (1.0)
CACNB4 1 (1.0) SCN1A 11 (10.7)
CASK 1 (1.0) SCN1B 1 (1.0)
CDKL5 9 (8.7) SCN2A 5 (4.9)
CHD2 8 (7.8) SCN3A 1 (1.0)
DNM1 2 (1.9) SCN8A 5 (4.9)
EEF1A2 2 (1.9) SLC6A1 3 (2.9)
GNAO1 1 (1.0) SLC9A6 2 (1.9)
GRIN2A 1 (1.0) STXBP1 7 (6.8)
HCN1 1 (1.0) SYN1 1 (1.0)
IQSEC2 1 (1.0) SYNGAP1 5 (4.9)
KANSL1 1 (1.0) UBE3A 2 (1.9)
KCNA1 1 (1.0) WWOX 1 (1.0)
KCNB1 2 (1.9) ZEB2 2 (1.9)
n, number
Table 2. Demographic characteristics of patients with developmental and epileptic
encephalopathy and comparison between patients with positive and negative results from
targeted gene-panel sequencing
Total
(n = 278)
Identified pathogenic
mutations (n = 103)
Negative results
(n = 175)
p
Age at seizure
onset (months)
7 (318) 6 (218) 7 (419) 0.039
Sex (male) 155 (55.8%) 51 (49.5%) 104 (59.4%) 0.108
Drug-resistant
epilepsy
161 (57.9%) 74 (71.8%) 87 (49.7%) < 0.001
Prior genetic
tests
107 (38.5%) 43 (41.7%) 64 (36.6%) 0.392
Data are presented as median (interquartile range) or number (percentage).
6
Figure 2. Positivity rate of targeted gene-panel sequencing for developmental and
epileptic encephalopathy according to epilepsy syndromes.
(WS, West syndrome; EIMFS, epilepsy of infancy with migrating focal seizures; GE,
generalized epilepsy; EMAS, epilepsy with myoclonic atonic seizures; LGS,
Lennox-Gastaut syndrome; LKS, Landau-Kleffner syndrome)
Figure 1. Age distribution of seizure onset in 103 patients with identified pathogenic
mutations (m, months). The right pie chart shows seizure onset age distribution of 0-12m
group in more detail.
7
III-2. Genotype-phenotype correlations
The 278 patients could be classified into 10 groups according to the epilepsy
syndromes; 119 (42.8%) were classified as showing WS. The diagnostic yield of the gene-panel
study differed significantly among patients with the different epilepsy syndromes (p < 0.001,),
with the highest diagnostic yield in patients with WS with neonatal seizures (100.0%), followed
by those with Ohtahara syndrome (85.7%), and others (Figure 2).
Figure 3 shows the range of ages at seizure onset in our patients and the mutations
identified in each epilepsy syndrome. For patients with WS with neonatal seizures, KCNQ2 and
STXBP1 were the most frequently identified disease-causing genes; for those with Ohtahara
syndrome, KCNQ2; for epilepsy of infancy with migrating focal seizures (EIMFS), KCNT1; for
WS, CDKL5; for Dravet syndrome, SCN1A; for Lennox-Gastaut syndrome (LGS), SYNGAP1;
for epilepsy with myoclonic atonic seizures (EMAS), SLC6A1; for unspecified generalized
epilepsy, CDH2; and for unspecified focal epilepsy, PCDH19.
Figure 3. Genotype-phenotype correlations. The bar indicates the range of seizure onset
age (months) observed in our cohort for each syndrome, and genes identified to have
disease-causing mutations for each syndrome are listed in an order of decreasing frequency.
The numbers before the genes indicate the identified frequency for each gene.
(WS, West syndrome; EIMFS, epilepsy of infancy with migrating focal seizures; LGS,
Lennox-Gastaut syndrome; EMAS, epilepsy with myoclonic atonic seizures; GE,
generalized epilepsy; FE, focal epilepsy)
8
Age of seizure onset for each genotype was relatively consistent, and the median onset
age of seizures was 3 days in patients with KCNQ2-related encephalopathy; 7 days in
STXBP1-related conditions; 1 month in KCNT1-related conditions; 3 months in CDKL5-,
SCN8A-, and BRAT1-related conditions; and 6 months in SCN1A-related conditions. The age at
seizure onset in patients with CHD2 and SYNGAP1 encephalopathy was relatively high, with a
median seizure onset age of 19 and 26 months, respectively (Figure 4).
The details of the clinical characteristics, including seizure outcomes according to
therapeutic regimens, are described below.
III-3. SCN1A (Sodium channel, neuronal type 1, alpha subunit)
Eleven patients were identified with mutations in SCN1A (sodium channel, neuronal
type 1, alpha subunit gene). A summary of the clinical characteristics are shown in Table 3. All
patients showed phenotypes that were concordant with Dravet syndrome. These 11 patients
comprised 61.1% of those with total Dravet syndrome (n = 18), with another 6 patients without
identified pathogenic variants and 1 with a mutation in SCN1B.
III-4. CDKL5 (Cyclin-dependent kinase-like 5)
Nine patients had mutations in the CDKL5 (cyclin-dependent kinase-like 5 gene) in our
study. Five patients presented with tonic seizures first, and shortly afterwards developed spasms
and later showed hypsarrhythmia on EEG and were diagnosed with WS. Two patients presented
with spasms with hypsarrhythmia on EEG, and were also diagnosed with WS. The remaining 2
Figure 4. Age of seizure onset according to genes identified with pathogenic mutations.
9
patients who had an earlier seizure onset age (15 and 50 days, respectively) presented with tonic
seizures with a burst-suppression pattern on EEG, and were diagnosed with Ohatahara
syndrome; the condition in both evolved into WS at the age of 3 months. All these patients
showed early developmental delay before seizure onset, and showed profound intellectual
disability (ID); 7 (77.8%) were unable to make eye contact or control their heads. All patients
also showed drug-resistant epilepsy, and a ketogenic diet (KD) was attempted in all 9 patients,
but was effective in only 1 patient. In 2 patients who were followed up for more than 10 years,
seizures evolved into LGS. Corpus callosotomy was performed in both of them, which resulted
in 50% and 75% seizure reduction after the surgery, respectively.
III-5. CHD2 (Chromodomain helicase DNA-binding protein 2)
Eight patients showed mutations in CHD2 (chromodomain helicase DNA-binding
protein 2 gene). All patients presented predominantly with myoclonic seizures, and clinical
photosensitivity was observed in 5 patients (62.5%). The EEGs of all these patients showed
generalized epileptiform discharges, and 2 patients were diagnosed with EMAS, 1 with LGS,
and 5 were classified as having unspecified generalized epilepsy. All patients showed normal
development until seizure onset, had their first seizures during childhood at a median age of 19
months, and showed developmental impairment after seizure onset. Five patients, with disease
duration of less than 10 years, currently show mild ID with relatively near normal social
quotients on the social maturity scale. However, 2 patients with longer follow-up periods have
shown continued developmental regression to severe ID. In 6 (75.0%) patients, valproate was
the most effective medication, while 2 (25.0%) patients have drug-resistant epilepsy.
III-6. KCNQ2 (Potassium channel, voltage-gated, KQT-like subfamily, member 2)
Seven patients were found to harbor mutations in KCNQ2 (potassium channel, voltage-gated,
KQT-like subfamily, member 2 gene). Patients with KCNQ2 encephalopathy showed the earliest
seizure onset, and all patients had seizure onset within the first 9 days of life. All patients
presented with tonic seizures, but EEGs of 4 patients showed a burst-suppression pattern, while
the other 3 patients showed focal epileptiform discharges. The former 4 patients were diagnosed
with Ohtahara syndrome, and the condition in all 7 patients later evolved into WS. All patients
showed profound ID, with none showing any signs of development. All patients had
drug-resistant epilepsy, but the KD had favorable responses in 6 patients. Sodium channel
blockers were administered in 4 patients and these were effective in controlling their seizures.
10
III-7. STXBP1 (Syntaxin-binding protein 1)
Seven patients had mutations in STXBP1 (syntaxin-binding protein 1 gene). The
median seizure onset age was 7 days, which was relatively early. Five patients presented with
focal or generalized seizures during the neonatal period, 2 were diagnosed with Ohtahara
syndrome with a burst-suppression pattern on EEG, and 3 showed focal epileptiform discharge.
The remaining 2 patients with a later seizure onset age, at 2 and 8 months, presented with
spasms, hypsarrhythmia on EEG, and were diagnosed with WS. The condition in the former 5
patients also evolved into WS. Seizures were drug resistant in half of the patients, and various
degrees (mild to severe) of ID were observed. Ketogenic diet was effective in seizure reduction
in all 4 patients who tried the dietary therapy.
III-8. SCN2A (Sodium channel, neuronal type 2, alpha subunit)
Five patients had pathogenic variants in SCN2A (sodium channel, neuronal
type 2, alpha subunit gene). The age of seizure onset had a bimodal distribution; 3 patients had
seizure onset at 1 day, 2 patients at 5 months, and 2 patients at 30 and 36 months each. The first
3 patients presented with Ohtahara syndrome and WS, which later evolved into LGS with a
significant developmental impact (3 were unable to make eye contact or control their heads).
Two patients with seizure onset at 1 day and 5 months, respectively, were given sodium channel
blockers and showed significant seizure reduction. One patient with seizure onset age of 5
months was not tried with sodium channel blockers. The other 2 patients with later seizure onset
age of 30 and 36 months were both diagnosed with LGS and unspecified focal epilepsy. Both
patients showed normal development before seizure onset, and regressed thereafter, currently
showing mild ID. Sodium channel blockers were administered to both patients without effect
and were discontinued.
III-9. SCN8A (Sodium channel, neuronal type 8, alpha subunit)
Five patients were identified with pathogenic variants in SCN8A (sodium
channel, neuronal type 8, alpha subunit gene). One patient presented with neonatal seizures that
later developed into WS, and the other 4 all presented with WS. Later, the condition in all 5
patients evolved into LGS, and the patients showed significant developmental delay. Three
patients (60.0%) had drug-resistant epilepsy; sodium channel blockers were administered to 4
patients, with a favorable response in 3 (75.0%) patients.
11
III-10. SYNGAP1 (Synaptic Ras-GTPase-activating protein 1)
Five patients had disease-causing variants in SYNGAP1 (synaptic
Ras-GTPase-activating protein 1 gene). The median seizure onset age was 26 months, which
was relatively late. All patients had generalized seizures, such as myoclonic, atonic, or atypical
absence seizures, with EEGs showing predominantly generalized epileptiform discharges. Four
patients were diagnosed with LGS and 1 with EMAS. In 1 (20.0%) patient, seizures were
intractable to medication. All patients showed developmental delay prior to seizure onset, and
currently show severe ID, except for 1 patient with moderate ID.
12
13
IV. DISCUSSION
We defined 35 different disease-causing monogenic mutations in 37.1% patients with
DEE. These patients had a lower age at seizure onset and had more intractable seizures than
patients in whom mutations were not identified with the gene panel screening.
With the advent of sequencing methods that enable sequencing of several DNA regions
in a single reaction, there have been significant advances in the identification of epilepsy-related
genes.2 Monogenic epilepsy, in which a single variant with a large effect is considered causative,
is far less common than complex genetic epilepsy, in which a combinatorial effect of multiple
variants is considered causative.5 However, previous studies with NGS gene panels for DEE
have shown substantial diagnostic yields of about 2040%, which is not inferior to the
diagnostic yield of whole exome sequencing.6-16 Some of recent studies include a study with 175
Chinese patients with early-onset epileptic encephalopathy investigated with gene panel
comprising 17 genes which identified disease-causing variants in 32% of patients, a study with
87 patients with epilepsy and developmental delay investigated with 106 genes gene panel in
which 19.5% of patients were identified with pathogenic variants, a study with 349 patients with
drug-resistant epilepsy and seizure onset before 1 year of age who were investigated with
95-genes gene panel and showed 26.6% of diagnostic yield, and a study with 400 patients with
early-onset seizures and severe developmental delay who were investigated with 46-genes gene
panel and showed 18% of diagnostic yield.13-16 Direct comparisons between studies for factors
influencing diagnostic yields are difficult as cohorts and genes included in the panels are
different, but slightly higher diagnostic yield in our study may be attributable to higher
availability of parental samples (90.1% of 131 patients whose parental samples were needed to
investigate variants with unknown significance) to confirm de novo occurrence of variants. In
41.7% of patients in whom disease-causing variants were identified in this study, results from
previous genetic tests prior to the gene-panel study were uninformative. Therefore, monogenic
variants, especially de novo variants, have an important role in DEE, and at present, targeted
gene-panel sequencing is the most cost-effective diagnostic option for epilepsy patients with
suspected genetic etiology.5,17
Here, the proportion of patients with drug-resistant epilepsy was significantly higher
among patients with identified mutations, which is concordant with the results of previous
reports that showed higher diagnostic yields in cohorts with severe drug-resistant epilepsy.5
These observations have not been explained to date; however, possible reasons are that patients
with somatic mutations occurring only in the brain, those with a low rate of mosaic mutations,
or patients with complex genetic epilepsy obtaining negative results in gene panels, may have
14
less severe symptoms than patients carrying monogenic mutations with large effects. The
seizure onset age was significantly lower in patients with identified mutations. This observation
is also in accord with those of previous studies, which showed that seizures with an earlier age
at onset resulted in higher molecular yields.15,17 The timing of seizure onset for each pathogenic
gene was relatively consistent among patients, as seizures started at the age at which the
expression of a gene with the pathogenic mutation is required for physiological neuronal
development.18 Therefore, patients with pathogenic monogenic variants with strong effects may
develop genetic dysfunctions earlier than patients with presumably somatic mosaicism or a
polygenic disease basis. Naturally, the diagnostic yields were also higher in catastrophic
epilepsy syndromes with earlier seizure onset, such as WS with neonatal seizure, Ohtahara
syndrome, and EIMFS.
Factors accounting for phenotypic pleiotropy can include the type and timing of
mutations, including somatic mosaicism or genomic rearrangements; localization of the
mutations in the protein; the loss- or gain-of-function mechanisms caused by the mutations;
epigenetic factors; and modifier genes.19-24 However, patients with the various pathogenic genes
do share some common features, such as the temporal expression of symptoms and the type of
epilepsy syndromes, as described above. This was more evident in some cases, such as in those
with KCNT1 mutations, where all 3 patients presented with EIMFS, and as in Dravet syndrome,
where patients almost exclusively had SCN1A as the causative gene (91.7% of genetically
diagnosed patients).
The ultimate goal of genetic diagnosis is targeted therapy. However, available therapies
targeted to known genetic mutations are still limited to a few genes, such as KD for SCL2A1,
retigabine for KCNQ2, memantine for GRIN2A or GRIN2B, and quinidine for KCNT1.25-29
Three EIMFS patients in our cohort who had pathogenic variants in KCNT1 showed intractable
seizures, and 2 of these were administered quinidine; this was discontinued for 1 patient before
the therapeutic level was reached due to QT prolongation, while another patient, in whom the
therapeutic serum concentration was reached, did not show any effects in seizure reduction.
Therefore, more studies are warranted for achieving targeted therapy, including reprogramming
of stem cells or gene therapy, based on molecular diagnoses.
In other cases, patients with each genetic mutation in this study showed clinical
characteristics that were similar to those described previously, and also similar responses to
specific therapies. Besides retigabine, sodium channel blockers are also known to be effective in
seizure control in KCNQ2 encephalopathy patients, probably through modulation of the sodium
channel that affects the function of the channel complex including the potassium channel.30,31 In
this study, sodium channel blockers were administered to 4 patients, and were effective but did
15
not completely control the seizures in all 4 patients. Wolff et al. reported that mutations in
SCN2A cause 2 distinct phenotypes: early infantile onset (<3 months) and infantile/childhood
onset (≥3 months) encephalopathies.32 The early infantile form was associated with
gain-of-function mutations, and therefore showed good response to sodium channel blockers,
while the later onset form was associated with a loss-of function and sodium channel blockers
were rarely effective or sometimes worsened the seizures.32 Also, early infantile form were all
identified with missense mutations, while later onset form was associated with both missense
and nonsense mutations, and patients with nonsense mutations all had seizure onset beyond the
first year of life. In our study, the patients could be distinguished into earlier and later onset
groups; earlier onset patients all had missense mutations and showed a good response to sodium
channel blockers, while they were not effective in later onset patients with non-sense mutations,
resulting in discontinuation of the medication. For mutations in SCN8A, most functional
analyses to date have revealed gain-of-function effects, but some variants also produced
loss-of-function effects in vitro.33 In our study, the majority (75.0%) of the patients showed a
good response to sodium channel blockers.
V. CONCLUSION
Monogenic mutations, especially de novo monogenic variants, are an important
underlying etiology for DEE, and targeted gene-panel sequencing is an effective diagnostic tool
for DEE. The diagnostic yield is higher in drug-resistant epilepsy, and in patients with earlier
seizure onset especially during the neonatal period. Although phenotypic pleiotropy exists, we
could confirm correlation of genotypes with the clinical progress and seizure outcomes to
specific therapeutic regimens that were similar to those described in previous studies.
16
REFERENCES
1 Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE
classification of the epilepsies: Position paper of the ILAE Commission for
Classification and Terminology. Epilepsia 2017; 58: 512-521.
2 Moller RS, Dahl HA, Helbig I. The contribution of next generation sequencing to
epilepsy genetics. Expert Rev Mol Diagn 2015; 15: 1531-1538.
3 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus recommendation
of the American College of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet Med 2015; 17: 405-424.
4 Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al.
Revised terminology and concepts for organization of seizures and epilepsies: report of
the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;
51: 676-685.
5 Mei D, Parrini E, Marini C, Guerrini R. The Impact of Next-Generation Sequencing on
the Diagnosis and Treatment of Epilepsy in Paediatric Patients. Mol Diagn Ther 2017;
doi:10.1007/s40291-017-0257-0.
6 Gokben S, Onay H, Yilmaz S, Atik T, Serdaroglu G, Tekin H, et al. Targeted next
generation sequencing: the diagnostic value in early-onset epileptic encephalopathy.
Acta Neurol Belg 2017; 117: 131-138.
7 Mercimek-Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, Donner EJ, et al.
Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia
2015; 56: 707-716.
8 de Kovel CG, Brilstra EH, van Kempen MJ, Van't Slot R, Nijman IJ, Afawi Z, et al.
Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large
cohort of patients. Mol Genet Genomic Med 2016; 4: 568-580.
9 Carvill GL, Heavin SB, Yendle SC, McMahon JM, O'Roak BJ, Cook J, et al. Targeted
resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and
SYNGAP1. Nat Genet 2013; 45: 825-830.
10 Michaud JL, Lachance M, Hamdan FF, Carmant L, Lortie A, Diadori P, et al. The
genetic landscape of infantile spasms. Hum Mol Genet 2014; 23: 4846-4858.
11 Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, et al. De novo
mutations in epileptic encephalopathies. Nature 2013; 501: 217-221.
12 Segal E, Pedro H, Valdez-Gonzalez K, Parisotto S, Gliksman F, Thompson S, et al.
17
Diagnostic Yield of Epilepsy Panels in Children With Medication-Refractory Epilepsy.
Pediatr Neurol 2016; 64: 66-71.
13 Zhang Q, Li J, Zhao Y, Bao X, Wei L, Wang J. Gene mutation analysis of 175 Chinese
patients with early-onset epileptic encephalopathy. Clin Genet 2017; 91: 717-724.
14 Ortega-Moreno L, Giraldez BG, Soto-Insuga V, Losada-Del Pozo R, Rodrigo-Moreno
M, Alarcon-Morcillo C, et al. Molecular diagnosis of patients with epilepsy and
developmental delay using a customized panel of epilepsy genes. PLoS One 2017; 12:
e0188978.
15 Parrini E, Marini C, Mei D, Galuppi A, Cellini E, Pucatti D, et al. Diagnostic Targeted
Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies
Causative Mutations in 30 Different Genes. Hum Mutat 2017; 38: 216-225.
16 Trump N, McTague A, Brittain H, Papandreou A, Meyer E, Ngoh A, et al. Improving
diagnosis and broadening the phenotypes in early-onset seizure and severe
developmental delay disorders through gene panel analysis. J Med Genet 2016; 53:
310-317.
17 Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, et al.
Diagnostic exome sequencing provides a molecular diagnosis for a significant
proportion of patients with epilepsy. Genet Med 2016; 18: 898-905.
18 McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of
the epileptic encephalopathies of infancy and childhood. Lancet Neurol 2016; 15:
304-316.
19 Gennaro E, Santorelli FM, Bertini E, Buti D, Gaggero R, Gobbi G, et al. Somatic and
germline mosaicisms in severe myoclonic epilepsy of infancy. Biochem Biophys Res
Commun 2006; 341: 489-493.
20 Seltzer LE, Ma M, Ahmed S, Bertrand M, Dobyns WB, Wheless J, et al. Epilepsy and
outcome in FOXG1-related disorders. Epilepsia 2014; 55: 1292-1300.
21 Syrbe S, Hedrich UBS, Riesch E, Djemie T, Muller S, Moller RS, et al. De novo loss-
or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat Genet
2015; 47: 393-399.
22 Miceli F, Soldovieri MV, Ambrosino P, Barrese V, Migliore M, Cilio MR, et al.
Genotype-phenotype correlations in neonatal epilepsies caused by mutations in the
voltage sensor of K(v)7.2 potassium channel subunits. Proc Natl Acad Sci U S A 2013;
110: 4386-4391.
23 Nakamura K, Kato M, Osaka H, Yamashita S, Nakagawa E, Haginoya K, et al. Clinical
spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology 2013; 81:
18
992-998.
24 Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe P, et al. A role of
SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of
Dravet syndrome. PLoS Genet 2009; 5: e1000649.
25 Kass HR, Winesett SP, Bessone SK, Turner Z, Kossoff EH. Use of dietary therapies
amongst patients with GLUT1 deficiency syndrome. Seizure 2016; 35: 83-87.
26 Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine),
a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012; 53:
412-424.
27 Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, et al. KCNT1 gain of
function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014; 75:
581-590.
28 Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, et al.
GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with
memantine. Ann Clin Transl Neurol 2014; 1: 190-198.
29 Platzer K, Yuan H, Schutz H, Winschel A, Chen W, Hu C, et al. GRIN2B
encephalopathy: novel findings on phenotype, variant clustering, functional
consequences and treatment aspects. J Med Genet 2017; 54: 460-470.
30 Nguyen HM, Miyazaki H, Hoshi N, Smith BJ, Nukina N, Goldin AL, et al. Modulation
of voltage-gated K+ channels by the sodium channel beta1 subunit. Proc Natl Acad Sci
U S A 2012; 109: 18577-18582.
31 Pisano T, Numis AL, Heavin SB, Weckhuysen S, Angriman M, Suls A, et al. Early and
effective treatment of KCNQ2 encephalopathy. Epilepsia 2015; 56: 685-691.
32 Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E, et al.
Genetic and phenotypic heterogeneity suggest therapeutic implications in
SCN2A-related disorders. Brain 2017; 140: 1316-1336.
33 Blanchard MG, Willemsen MH, Walker JB, Dib-Hajj SD, Waxman SG, Jongmans MC,
et al. De novo gain-of-function and loss-of-function mutations of SCN8A in patients
with intellectual disabilities and epilepsy. J Med Genet 2015; 52: 330-337.
19
APPENDICES
Appendix 1. List of 172 targeted genes included in the developmental and epileptic
encephalopathy panel
Gene OMIM Full name Cytogenetic
location
AARS 601065 ALANYL-tRNA SYNTHETASE 16q22.1
ABAT 137150 4-AMINOBUTYRATE AMINOTRANSFERASE 16p13.2
ACADL 609576 ACYL-CoA DEHYDROGENASE,
LONG-CHAIN
2q34
ACADM 607008 ACYL-CoA DEHYDROGENASE,
MEDIUM-CHAIN
1p31.1
ACADS 606885 ACYL-CoA DEHYDROGENASE,
SHORT-CHAIN
12q24.31
ACY1 104620 AMINOACYLASE 1 3p21.2
ADGRV1 602851 ADHESION G PROTEIN-COUPLED
RECEPTOR V1
5q14.3
ADSL 608222 ADENYLOSUCCINATE LYASE 22q13.1
ALAD 125270 DELTA-AMINOLEVULINATE
DEHYDRATASE
9q32
ALAS2 301300 DELTA-AMINOLEVULINATE SYNTHASE 2 Xp11.21
ALDH4A1 606811 ALDEHYDE DEHYDROGENASE, FAMILY 4,
SUBFAMILY A, MEMBER 1
1p36.13
ALDH7A1 107323 ALDEHYDE DEHYDROGENASE 7 FAMILY,
MEMBER A1
5q23.2
ALG13 300776 ASPARAGINE-LINKED GLYCOSYLATION 13 Xq23
ALPL 171760 ALKALINE PHOSPHATASE, LIVER 1p36.12
AMT 238310 AMINOMETHYLTRANSFERASE 3p21.31
ARHGEF15 608504 RHO GUANINE NUCLEOTIDE EXCHANGE
FACTOR 15
17p13.1
ARHGEF9 300429 RHO GUANINE NUCLEOTIDE EXCHANGE
FACTOR 9
Xq11.1
ARX 300382 ARISTALESS-RELATED HOMEOBOX,
X-LINKED
Xp21.3
ASNS 108370 ASPARAGINE SYNTHETASE 7q21.3
ASPM 605481 ABNORMAL SPINDLE-LIKE,
MICROCEPHALY-ASSOCIATED
1q31.3
ATP13A2 610513 ATPase, TYPE 13A2 1p36.13
ATP6AP2 300556 ATPase, H+ TRANSPORTING, LYSOSOMAL,
ACCESSORY PROTEIN 2
Xp11.4
BRAT1 614506 BRCA1-ASSOCIATED ATM ACTIVATOR 1 7p22.3
BTD 609019 BIOTINIDASE 3p25.1
CACNA1A 601011 CALCIUM CHANNEL,
VOLTAGE-DEPENDENT, P/Q TYPE,
ALPHA-1A SUBUNIT
19p13.13
CACNB4 601949 CALCIUM CHANNEL,
VOLTAGE-DEPENDENT, BETA-4 SUBUNIT
2q23.3
CASK 300172 CALCIUM/CALMODULIN-DEPENDENT
SERINE PROTEIN KINASE
Xp11.4
CASR 601199 CALCIUM-SENSING RECEPTOR 3q13.3-q21.1
20
CBS 613381 CYSTATHIONINE BETA-SYNTHASE 21q22.3
CDKL5 300203 CYCLIN-DEPENDENT KINASE-LIKE 5 Xp22.13
CHD2 602119 CHROMODOMAIN HELICASE
DNA-BINDING PROTEIN 2
15q26.1
CHRNA2 118502 CHOLINERGIC RECEPTOR, NEURONAL
NICOTINIC, ALPHA POLYPEPTIDE 2
8p21.2
CHRNA4 118504 CHOLINERGIC RECEPTOR, NEURONAL
NICOTINIC, ALPHA POLYPEPTIDE 4
20q13.33
CHRNA7 118511 CHOLINERGIC RECEPTOR, NEURONAL
NICOTINIC, ALPHA POLYPEPTIDE 7
15q13.3
CHRNB2 118507 CHOLINERGIC RECEPTOR, NEURONAL
NICOTINIC, BETA POLYPEPTIDE 2
1q21.3
CLCN4 302910 CHLORIDE CHANNEL 4 Xp22.2
CLN3 607042 CLN3 GENE 16p12.1
CLN5 608102 CLN5 GENE 13q22.3
CLN6 606725 CLN6 GENE 15q23
CLN8 607837 CLN8 GENE 8p23.3
CNTNAP2 604569 CONTACTIN-ASSOCIATED PROTEIN-LIKE 2 7q35-q36
COL4A1 120130 COLLAGEN, TYPE IV, ALPHA-1 13q34
CPOX 612732 COPROPORPHYRINOGEN OXIDASE 3q11.2
CPT1A 600528 CARNITINE PALMITOYLTRANSFERASE I,
LIVER
11q13.3
CPT1B 601987 CARNITINE PALMITOYLTRANSFERASE I,
MUSCLE
22q13.33
CPT2 600650 CARNITINE PALMITOYLTRANSFERASE II 1p32.3
CSTB 601145 CYSTATIN B 21q22.3
CTSD 116840 CATHEPSIN D 11p15.5
CTSF 603539 CATHEPSIN F 11q13.2
DNAJC5 611203 DNAJ/HSP40 HOMOLOG, SUBFAMILY C,
MEMBER 5
20q13.33
DNM1 602377 DYNAMIN 1 9q34.11
DOCK7 615730 DEDICATOR OF CYTOKINESIS 7 1p31.3
DYRK1A 600855 DUAL-SPECIFICITY TYROSINE
PHOSPHORYLATION-REGULATED KINASE
1A
21q22.13
EEF1A2 602959 EUKARYOTIC TRANSLATION ELONGATION
FACTOR 1, ALPHA-2
20q13.33
EPM2A 607566 EPM2A GENE 6q24.3
FARS2 611592 PHENYLALANYL-tRNA SYNTHETASE 2,
MITOCHONDRIAL
6p25.1
FECH 612386 FERROCHELATASE 18q21.31
FOLR1 136430 FOLATE RECEPTOR 1, ADULT 11q13.4
FOXG1 164874 FORKHEAD BOX G1 14q12
GABBR2 607340 GAMMA-AMINOBUTYRIC ACID B
RECEPTOR 2
9q22.33
GABRA1 137160 GAMMA-AMINOBUTYRIC ACID
RECEPTOR, ALPHA-1
5q34
GABRB3 137192 GAMMA-AMINOBUTYRIC ACID
RECEPTOR, BETA-3
15q12
GABRG2 137164 GAMMA-AMINOBUTYRIC ACID
RECEPTOR, GAMMA-2
5q34
GAMT 601240 GUANIDINOACETATE
METHYLTRANSFERASE
19p13.3
21
GATM 602360 L-ARGININE:GLYCINE
AMIDINOTRANSFERASE
15q21.1
GCSH 238330 GLYCINE CLEAVAGE SYSTEM H PROTEIN 16q23.2
GLDC 238300 GLYCINE DECARBOXYLASE 9p24.1
GNAO1 139311 GUANINE NUCLEOTIDE-BINDING
PROTEIN, ALPHA-ACTIVATING ACTIVITY
POLYPEPTIDE O
16q13
GOSR2 604027 GOLGI SNAP RECEPTOR COMPLEX
MEMBER 2
17q21.32
GRIN1 138249 GLUTAMATE RECEPTOR, IONOTROPIC,
N-METHYL-D-ASPARTATE, SUBUNIT 1
9q34.3
GRIN2A 138253 GLUTAMATE RECEPTOR, IONOTROPIC,
N-METHYL-D-ASPARTATE, SUBUNIT 2A
16p13.2
GRIN2B 138252 GLUTAMATE RECEPTOR, IONOTROPIC,
N-METHYL-D-ASPARTATE, SUBUNIT 2B
12p13.1
GRN 138945 GRANULIN PRECURSOR 17q21.31
HADH 601609 3-HYDROXYACYL-CoA DEHYDROGENASE 4q25
HADHA 600890 HYDROXYACYL-CoA
DEHYDROGENASE/3-KETOACYL-CoA
THIOLASE/ENOYL-CoA HYDRATASE,
ALPHA SUBUNIT
2p23.3
HCN1 602780 HYPERPOLARIZATION-ACTIVATED CYCLIC
NUCLEOTIDE-GATED POTASSIUM
CHANNEL 1
5p12
HCN4 605206 HYPERPOLARIZATION-ACTIVATED CYCLIC
NUCLEOTIDE-GATED POTASSIUM
CHANNEL 4
15q24.1
HFE 613609 HFE GENE 6p22.2
HLCS 609018 HOLOCARBOXYLASE SYNTHETASE 21q22.13
HMBS 609806 HYDROXYMETHYLBILANE SYNTHASE 11q23.3
HNRNPU 602869 HETEROGENEOUS NUCLEAR
RIBONUCLEOPROTEIN U
1q44
IQSEC2 300522 IQ MOTIF- AND SEC7
DOMAIN-CONTAINING PROTEIN 2
Xp11.22
KANSL1 612452 KAT8 REGULATORY NSL COMPLEX,
SUBUNIT 1
17q21.31
KCNA1 176260 POTASSIUM CHANNEL, VOLTAGE-GATED,
SHAKER-RELATED SUBFAMILY, MEMBER 1
12p13.32
KCNA2 176262 POTASSIUM CHANNEL, VOLTAGE-GATED,
SHAKER-RELATED SUBFAMILY, MEMBER 2
1p13.3
KCNB1 600397 POTASSIUM CHANNEL, VOLTAGE-GATED,
SHAB-RELATED SUBFAMILY, MEMBER 1
20q13.13
KCNC1 176258 POTASSIUM CHANNEL, VOLTAGE-GATED,
SHAW-RELATED SUBFAMILY, MEMBER 1
11p15.1
KCNH5 605716 POTASSIUM CHANNEL, VOLTAGE-GATED,
SUBFAMILY H, MEMBER 5
14q23.2
KCNJ10 602208 POTASSIUM CHANNEL, INWARDLY
RECTIFYING, SUBFAMILY J, MEMBER 10
1q23.2
KCNJ11 600937 POTASSIUM CHANNEL, INWARDLY
RECTIFYING, SUBFAMILY J, MEMBER 11
11p15.1
KCNMA1 600150 POTASSIUM CHANNEL,
CALCIUM-ACTIVATED, LARGE
CONDUCTANCE, SUBFAMILY M, ALPHA
10q22.3
22
MEMBER 1
KCNQ2 602235 POTASSIUM CHANNEL, VOLTAGE-GATED,
KQT-LIKE SUBFAMILY, MEMBER 2
20q13.33
KCNQ3 602232 POTASSIUM CHANNEL, VOLTAGE-GATED,
KQT-LIKE SUBFAMILY, MEMBER 3
8q24.22
KCNT1 608167 POTASSIUM CHANNEL, SUBFAMILY T,
MEMBER 1
9q34.3
KCTD7 611725 POTASSIUM CHANNEL TETRAMERIZATION
DOMAIN-CONTAINING PROTEIN 7
7q11.21
KPNA7 614107 KARYOPHERIN ALPHA-7 7q22.1
LGI1 604619 LEUCINE-RICH GENE,
GLIOMA-INACTIVATED, 1
10q23.33
LIAS 607031 LIPOIC ACID SYNTHASE 4p14
MAGI2 606382 MEMBRANE-ASSOCIATED GUANYLATE
KINASE, WW AND PDZ
DOMAINS-CONTAINING, 2
7q21.11
MBD5 611472 METHYL-CpG-BINDING DOMAIN PROTEIN
5
2q23.1
MECP2 300005 METHYL-CpG-BINDING PROTEIN 2 Xq28
MEF2C 600662 MADS BOX TRANSCRIPTION ENHANCER
FACTOR 2, POLYPEPTIDE C
5q14.3
MFSD8 611124 MAJOR FACILITATOR SUPERFAMILY
DOMAIN-CONTAINING PROTEIN 8
4q28.2
MMADHC 611935 MMADHC GENE 2q23.2
MTHFR 607093 5,10-METHYLENETETRAHYDROFOLATE
REDUCTASE
1p36.22
MTR 156570 5-METHYLTETRAHYDROFOLATE-HOMOCY
STEINE S-METHYLTRANSFERASE
1q43
MTRR 602568 METHIONINE SYNTHASE REDUCTASE 5p15.31
NECAP1 611623 NECAP ENDOCYTOSIS-ASSOCIATED
PROTEIN 1
12p13.31
NHLRC1 608072 NHL REPEAT-CONTAINING 1 GENE 6p22.3
NRXN1 600565 NEUREXIN I 2p16.3
OPHN1 300127 OLIGOPHRENIN 1 Xq12
PAH 612349 PHENYLALANINE HYDROXYLASE 12q23.2
PC 608786 PYRUVATE CARBOXYLASE 11q13.2
PCDH19 300460 PROTOCADHERIN 19 Xq22.1
PHGDH 606879 PHOSPHOGLYCERATE DEHYDROGENASE 1p12
PIGA 311770 PHOSPHATIDYLINOSITOL GLYCAN
ANCHOR BIOSYNTHESIS CLASS A PROTEIN
Xp22.2
PIGQ 605754 PHOSPHATIDYLINOSITOL GLYCAN
ANCHOR BIOSYNTHESIS CLASS Q
PROTEIN
16p13.3
PLCB1 607120 PHOSPHOLIPASE C, BETA-1 20p12.3
PNKP 605610 POLYNUCLEOTIDE KINASE 3-PRIME
PHOSPHATASE
19q13.33
PNPO 603287 PYRIDOXAMINE 5-PRIME-PHOSPHATE
OXIDASE
17q21.32
POLG 174763 POLYMERASE, DNA, GAMMA 15q26.1
PPOX 600923 PROTOPORPHYRINOGEN OXIDASE 1q23.3
PPT1 600722 PALMITOYL-PROTEIN THIOESTERASE 1 1p34.2
PRICKLE1 608500 PRICKLE, DROSOPHILA, HOMOLOG OF, 1 12q12
PRICKLE2 608501 PRICKLE, DROSOPHILA, HOMOLOG OF, 2 3p14.1
23
PRODH 606810 PROLINE DEHYDROGENASE (OXIDASE) 1 22q11.21
PRRT2 614386 PROLINE-RICH TRANSMEMBRANE
PROTEIN 2
16p11.2
PURA 600473 PURINE-RICH ELEMENT-BINDING PROTEIN
A
5q31.3
QARS 603727 GLUTAMINYL-tRNA SYNTHETASE 3p21.31
SCARB2 602257 SCAVENGER RECEPTOR CLASS B,
MEMBER 2
4q21.1
SCN1A 182389 SODIUM CHANNEL, NEURONAL TYPE I,
ALPHA SUBUNIT
2q24.3
SCN1B 600235 SODIUM CHANNEL, VOLTAGE-GATED,
TYPE I, BETA SUBUNIT
19q13.11
SCN2A 182390 SODIUM CHANNEL, VOLTAGE-GATED,
TYPE II, ALPHA SUBUNIT
2q24.3
SCN3A 182391 SODIUM CHANNEL, VOLTAGE-GATED,
TYPE III, ALPHA SUBUNIT
2q24.3
SCN8A 600702 SODIUM CHANNEL, VOLTAGE-GATED,
TYPE VIII, ALPHA SUBUNIT
12q13.13
SCN9A 603415 SODIUM CHANNEL, VOLTAGE-GATED,
TYPE IX, ALPHA SUBUNIT
2q24.3
SETBP1 611060 SET-BINDING PROTEIN 1 18q12.3
SIK1 605705 SALT-INDUCIBLE KINASE 1 21q22.3
SLC13A5 608305 SOLUTE CARRIER FAMILY 13
(SODIUM-DEPENDENT CITRATE
TRANSPORTER), MEMBER 5
17p13.1
SLC19A3 606152 SOLUTE CARRIER FAMILY 19 (THIAMINE
TRANSPORTER), MEMBER 3
2q36.3
SLC22A5 603377 SOLUTE CARRIER FAMILY 22 (ORGANIC
CATION TRANSPORTER), MEMBER 5
5q31.1
SLC25A20 613698 SOLUTE CARRIER FAMILY 25
(CARNITINE/ACYLCARNITINE
TRANSLOCASE), MEMBER 20
3p21.31
SLC25A22 609302 SOLUTE CARRIER FAMILY 25
(MITOCHONDRIAL CARRIER,
GLUTAMATE), MEMBER 22
11p15.5
SLC25A29 615064 SOLUTE CARRIER FAMILY 25
(CARNITINE/ACYLCARNITINE
TRANSLOCASE), MEMBER 29
14q32.2
SLC2A1 138140 SOLUTE CARRIER FAMILY 2 (FACILITATED
GLUCOSE TRANSPORTER), MEMBER 1
1p34.2
SLC46A1 611672 SOLUTE CARRIER FAMILY 46 (FOLATE
TRANSPORTER), MEMBER 1
17q11.2
SLC6A1 137165 SOLUTE CARRIER FAMILY 6
(NEUROTRANSMITTER TRANSPORTER,
GABA), MEMBER 1
3p25.3
SLC6A8 300036 SOLUTE CARRIER FAMILY 6
(NEUROTRANSMITTER TRANSPORTER,
CREATINE), MEMBER 8
Xq28
SLC9A6 300231 SOLUTE CARRIER FAMILY 9, MEMBER 6 Xq26.3
SMARCA2 600014 SWI/SNF-RELATED, MATRIX-ASSOCIATED,
ACTIN-DEPENDENT REGULATOR OF
CHROMATIN, SUBFAMILY A, MEMBER 2
9p24.3
SPTAN1 182810 SPECTRIN, ALPHA, NONERYTHROCYTIC 1 9q34.11
24
SRPX2 300642 SUSHI REPEAT-CONTAINING PROTEIN,
X-LINKED, 2
Xq22.1
ST3GAL3 606494 ST3 BETA-GALACTOSIDE
ALPHA-2,3-SIALYLTRANSFERASE 3
1p34.1
ST3GAL5 604402 ST3 BETA-GALACTOSIDE
ALPHA-2,3-SIALYLTRANSFERASE 5
2p11.2
STX1B 601485 SYNTAXIN 1B 16p11.2
STXBP1 602926 SYNTAXIN-BINDING PROTEIN 1 9q34.11
SYN1 313440 SYNAPSIN I Xp11.3-p11.2
SYNGAP1 603384 SYNAPTIC RAS-GTPase-ACTIVATING
PROTEIN 1
6p21.32
SZT2 615463 SEIZURE THRESHOLD 2, MOUSE,
HOMOLOG OF
1p34.2
TBC1D24 613577 TBC1 DOMAIN FAMILY, MEMBER 24 16p13.3
TBL1XR1 608628 TRANSDUCIN-BETA-LIKE 1 RECEPTOR 1 3q26.32
TCF4 602272 TRANSCRIPTION FACTOR 4 18q21.2
TNK2 606994 TYROSINE KINASE, NONRECEPTOR, 2 3q29
TPP1 607998 TRIPEPTIDYL PEPTIDASE I 11p15.4
TSEN54 608755 tRNA SPLICING ENDONUCLEASE 54, S.
CEREVISIAE, HOMOLOG OF
17q25.1
UBE2A 312180 UBIQUITIN-CONJUGATING ENZYME E2A Xq24
UBE3A 601623 UBIQUITIN-PROTEIN LIGASE E3A 15q11.2
UROD 613521 UROPORPHYRINOGEN DECARBOXYLASE 1p34.1
UROS 606938 UROPORPHYRINOGEN III SYNTHASE 10q26.2
WDR62 613583 WD REPEAT-CONTAINING PROTEIN 62 19q13.12
WWOX 605131 WW DOMAIN-CONTAINING
OXIDOREDUCTASE
16q23.1-q23.2
ZEB2 605802 ZINC FINGER E BOX-BINDING HOMEOBOX
2
2q22.3
25
Appendix 2. Pathogenic variants identified in this study
Patient Gene Nucleotide Amino acid Zygosity
1 ALDH7A1 c.1279G>C p.Glu427Gln Hetero
ALDH7A1 c.192+3A>T Hetero
2 ALDH7A1 c.192+3A>T Hetero
ALDH7A1 c.1093+5G>T Hetero
3 ARX c.995G>A p.Arg332His Hetero
4 BRAT1 c.1276C>T p.Gln426Ter Hetero
BRAT1 c.707T>G p.Leu236Arg Hetero
5 BRAT1 c.1276C>T p.Gln426Ter Hetero
BRAT1 c.707T>G p.Leu236Arg Hetero
6 BRAT1 Exon 2-3 deletion Hetero
BRAT1 c.1576C>T p.Gln526Ter Hetero
7 CACNA1A c.526G>A p.Val176Met Hetero
8 CACNB4* c.21delC p.Lys8ArgfsTer26 Hetero
9 CASK c.533-1G>C Hemi
10 CDKL5 c.145+2T>A Hemi
11 CDKL5* c.978-1G>A Hetero
12 CDKL5* c.282+1G>A Hetero
13 CDKL5* c.458A>T p.Asp153Val Hetero
14 CDKL5 c.511T>A p.Tyr171Asn Hetero
15 CDKL5 c.403+1G>A Hetero
16 CDKL5 c.175C>T p.Arg59Ter Hemi
17 CDKL5 c.513C>A p.Tyr171Ter Hetero
18 CDKL5* c.2354dupA p.Lys786GlufsTer15 Hetero
19 CHD2 c.361C>T p.Arg121Ter Hetero
20 CHD2* c.3885dupA p.Ile1296AsnfsTer8 Hetero
21 CHD2* c.1269dupA p.Glu424ArgfsTer3 Hetero
22 CHD2* c.1453C>T p.Arg485Ter Hetero
23 CHD2 Exon 5 deletion Hetero
24 CHD2 c.4507C>T p.Arg1503Trp Hetero
25 CHD2* c.3172G>T p.Glu1058Ter Hetero
26 CHD2* c.1897_1898delCT p.Leu633AspfsTer2 Hetero
27 DNM1* c.1195A>G p.Arg399Gly Hetero
28 DNM1* c.632A>T p.Asp211Val Hetero
29 EEF1A2 c.208G>A p.Gly70Ser Hetero
30 EEF1A2* c.294C>G p.Phe98Leu Hetero
31 GNAO1* c.155A>C p.Gln52Pro Hetero
32 GRIN2A c.1592C>T p.Thr531Met Hetero
33 HCN1* Exon 1-5 duplication Hetero
34 IQSEC2* c.136G>T p.Glu46Ter Hetero
35 KANSL1 Exon 2-3 duplication Hetero
36 KCNA1 c.1112C>T p.Thr371Ile Hetero
37 KCNB1 c.1135G>A p.Gly379Arg Hetero
38 KCNB1 c.1135G>A p.Gly379Arg Hetero
39 KCNQ2 c.773A>T p.Asn258Ile Hetero
40 KCNQ2 c.917C>T p.Ala306Val Hetero
41 KCNQ2 c.338C>T p.Ser113Phe Hetero
42 KCNQ2 c.1639C>T p.Arg547Trp Hetero
43 KCNQ2 c.638G>A p.Arg213Gln Hetero
44 KCNQ2 c.794C>T p.Ala265Val Hetero
26
45 KCNQ2 c.593G>A p.Arg198Gln Hetero
46 KCNT1 c.1421G>A p.Arg474His Hetero
47 KCNT1 c.2800G>A p.Ala934Thr Hetero
48 KCNT1* c.1038C>G p.Phe346Leu Hetero
49 MECP2 c.1164_1207delACCTCC
ACCTGAGCCCGAGAG
CTCCGAGGACCCCAC
CAGCCCCC
p.Pro389Ter Hetero
50 MECP2 Whole gene duplication Hetero
51 MECP2 Whole gene duplication Hetero
52 MECP2 Whole gene duplication Hetero
53 MECP2 c.502C>T p.Arg168Ter Hetero
54 PCDH19 Whole gene deletion Hetero
55 PCDH19 c.1019A>G p.Asn340Ser Hetero
56 PCDH19 Whole gene deletion Hetero
57 PRODH Whole exon deletion Hetero
58 SCN1A c.1154A>G p.Glu385Gly Hetero
59 SCN1A* c.644_655delTGAGAAC
ATTCA
p.Leu215_Arg219delinsT
er
Hetero
60 SCN1A Exon 20 deletion Hetero
61 SCN1A c.249C>G p.Tyr83Ter Hetero
62 SCN1A c.2210G>A p.Trp737Ter Hetero
63 SCN1A* c.5532dupC p.Met1845HisfsTer5 Hetero
64 SCN1A c.4306-1G>A Hetero
65 SCN1A* c.5163delC p.Ile1722PhefsTer46 Hetero
66 SCN1A Exon 7-16 deletion Hetero
67 SCN1A* c.2522T>C p.Val841Ala Hetero
68 SCN1A Whole exon deletion Hetero
69 SCN1B Exon 1-2 deletion Hetero
70 SCN2A* c.5308A>G p.Met1770Val Hetero
71 SCN2A* c.5327T>C p.Leu1776Pro Hetero
72 SCN2A c.5317G>A p.Ala1773Thr Hetero
73 SCN2A c.2516C>T p.Ala839Val Hetero
74 SCN2A c.1747C>T p.Arg583Ter Hetero
75 SCN3A Exon 9 duplication Hetero
76 SCN8A* c.424A>G p.Ile142Val Hetero
77 SCN8A c.2549G>A p.Arg850Gln Hetero
78 SCN8A c.5614C>T p.Arg1872Trp Hetero
79 SCN8A* c.782G>T p.Cys261Phe Hetero
80 SCN8A c.4423G>A p.Gly1475Arg Hetero
81 SLC6A1 Whole gene deletion Hetero
82 SLC6A1* c.1435C>T p.Arg479Ter Hetero
83 SLC6A1* c.694G>C p.Gly232Arg Hetero
84 SLC9A6 c.316_325+28delATGAT
TTATGGCAAGTTCCTC
AACCCTTGTCAGCCC
CT
Hemi
85 SLC9A6* c.589delT p.Tyr197IlefsTer3 Hemi
86 STXBP1* c.84G>A p.Trp28Ter Hetero
87 STXBP1 c.733C>G p.His245Asp Hetero
88 STXBP1 c.581_582dupAA p.Tyr195AsnfsTer11 Hetero
89 STXBP1 c.1216C>T p.Arg406Cys Hetero
90 STXBP1* Exon 7-10 deletion Hetero
27
91 STXBP1 c.874C>T p.Arg292Cys Hetero
92 STXBP1* c.1497C>G p.Tyr499Ter Hetero
93 SYN1 Whole gene duplication Hetero
94 SYNGAP1* c.2014delA p.Thr672ArgfsTer2 Hetero
95 SYNGAP1* c.557T>A p.Leu186Ter Hetero
96 SYNGAP1 c.2764C>T p.Arg922Ter Hetero
97 SYNGAP1 c.1735C>T p.Arg579Ter Hetero
98 SYNGAP1 c.980T>C p.Leu327Pro Hetero
99 UBE3A c.2294+1G>A Hetero
100 UBE3A Whole gene deletion Hetero
101 WWOX Exon 6-8 duplication Hetero
WWOX c.1060C>T p.Gln354Ter Hetero
102 ZEB2 c.1956C>A p.Tyr652Ter Hetero
103 ZEB2* c.2348dupC p.Ser784PhefsTer11 Hetero
28
ABSTRACT (IN KOREAN)
뇌전증성 뇌병증 환아에서 차세대 염기서열분석 유전자 패널과
유전형-표현형 연관성 연구
연세대학교 대학원 의학과
(지도교수: 강훈철)
고아라
뇌전증성 뇌병증 환아를 대상으로 차세대 염기서열분석 유전자 패널
검사를 시행하였고, 임상적으로 유전형-표현형 연관성을 조사하는 것이 이
연구의 목적이다.
뇌전증성 뇌병증 환아 278명에 대해 172개의 유전자로 이루어진 유전자
패널 검사를 시행하였고, 유전형에 따라 환자들의 치료 효과를 포함한
임상적 특징을 조사하였다.
278명의 뇌전증성 뇌병증 환아 중 103명 (37.1%)에게서 원인 유전자
변이가 확인되었으며, 총 35개의 유전자가 원인 유전자로 밝혀졌다.
진단율은 첫 경련이 어릴 때에 발생했을 수록, 특히 신생아기에 했을 때,
또한 약물 저항성 뇌전증을 보일수록 높았다. 뇌전증 증후군 별로 보았을
때는, 신생아 경련의 과거력이 있는 웨스트 증후군 환아에게서 진단율이
가장 높았으며, KCNQ2와 STXBP1의 변이가 가장 자주 보였다. 유전형 별로
임상적 경과와 각 치료법에 따른 경련 조절 여부도 조사하였을 때 이전
보고와 비슷한 결과가 나왔으며, KCNQ2, 영아기에 발생한 SCN2A, SCN8A
변이로 인한 뇌병증에서 나트륨통로차단제가 효과적이었으며, SCN1A, CDKL5,
KCNQ2, STXBP1, SCN2A 변이에서 케톤생성식이요법은 다양한 반응을 보였다.
2명의 KCNT1 변이를 보이는 영아기 이주성 부분 뇌전증 환아에서 quinidine
투여를 시도해 보았으나, 경련 발작에 효과를 보이지는 않았다.
차세대 염기서열분석 유전자 패널은 뇌전증성 뇌병증 환아에게 유용한
진단 도구이며, 유전형-표현형 연관성은 이러한 환아에서 임상적 예후 및
치료 효과를 예측하는데 도움이 된다.
----------------------------------------------------------------------------------------
핵심되는 말: 뇌전증성 뇌병증, 차세대 염기서열분석, 유전형-표현형
29
PUBLICATION LIST
Ko, A, Youn, SE, Kim, SH, Lee, JS, Kim, S, Choi, JR, et al. Targeted gene panel and
genotype-phenotype correlation in children with developmental and epileptic
enceaphlopathy. Epilepsy research 2018; 141: 48-55.